These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32521648)

  • 1. Mutant p53 as an Antigen in Cancer Immunotherapy.
    Sobhani N; D'Angelo A; Wang X; Young KH; Generali D; Li Y
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P53 and The Immune Response: 40 Years of Exploration-A Plan for the Future.
    Levine AJ
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31952115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53: a potential target antigen for immunotherapy of cancer.
    Offringa R; Vierboom MP; van der Burg SH; Erdile L; Melief CJ
    Ann N Y Acad Sci; 2000 Jun; 910():223-33; discussion 233-6. PubMed ID: 10911916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies.
    Chasov V; Zaripov M; Mirgayazova R; Khadiullina R; Zmievskaya E; Ganeeva I; Valiullina A; Rizvanov A; Bulatov E
    Front Immunol; 2021; 12():707734. PubMed ID: 34484205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P53: A Guardian of Immunity Becomes Its Saboteur through Mutation.
    Agupitan AD; Neeson P; Williams S; Howitt J; Haupt S; Haupt Y
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32414156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of vaccines against self-antigens: the p53 paradigm.
    Chada S; Mhashilkar A; Roth JA; Gabrilovich D
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):169-73. PubMed ID: 12669451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of cancer through targeting of the p53 tumor antigen.
    Zwaveling S; Van der Burg SH; Menon AG; Melief CJ; Offringa R
    Arch Immunol Ther Exp (Warsz); 2002; 50(5):297-305. PubMed ID: 12455863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the anti-p53 antibody response in cancer patients.
    Labrecque S; Naor N; Thomson D; Matlashewski G
    Cancer Res; 1993 Aug; 53(15):3468-71. PubMed ID: 8339249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen.
    Low L; Goh A; Koh J; Lim S; Wang CI
    Nat Commun; 2019 Nov; 10(1):5382. PubMed ID: 31772160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum p53 antibodies as early markers of lung cancer.
    Lubin R; Zalcman G; Bouchet L; Trédanel J; Legros Y; Cazals D; Hirsch A; Soussi T
    Nat Med; 1995 Jul; 1(7):701-2. PubMed ID: 7585154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant.
    Chai D; Wang J; Fan C; Lim JM; Wang X; Neeli P; Yu X; Young KH; Li Y
    J Hematol Oncol; 2024 Jun; 17(1):45. PubMed ID: 38886748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting p53 as a general tumor antigen.
    Theobald M; Biggs J; Dittmer D; Levine AJ; Sherman LA
    Proc Natl Acad Sci U S A; 1995 Dec; 92(26):11993-7. PubMed ID: 8618830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.
    Murakami T; Tokunaga N; Waku T; Gomi S; Kagawa S; Tanaka N; Fujiwara T
    Clin Cancer Res; 2004 Jun; 10(11):3871-80. PubMed ID: 15173096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53-based immunotherapy of cancer.
    DeLeo AB
    Crit Rev Immunol; 1998; 18(1-2):29-35. PubMed ID: 9419445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wildtype p53-specific antibody and T-cell responses in cancer patients.
    Pedersen AE; Stryhn A; Justesen S; Harndahl M; Rasmussen S; Donskov F; Claesson MH; Pedersen JW; Wandall HH; Svane IM; Buus S
    J Immunother; 2011; 34(9):629-40. PubMed ID: 21989411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Taurine Transporter (TauT) for Cancer Immunotherapy of p53 Mutation Mediated Cancers - Molecular Basis and Preclinical Implication.
    Han X
    Adv Exp Med Biol; 2019; 1155():543-553. PubMed ID: 31468430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The p53 Saga: Early Steps in the Development of Tumor Immunotherapy.
    DeLeo AB; Appella E
    J Immunol; 2020 May; 204(9):2321-2328. PubMed ID: 32312843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
    Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
    Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.